MS Academy Educational Webinars
Hot topics that matter today: Clinical vulnerability and vaccination
The MS Academy is a medical education initiative by Bayer AG. The 2021 program focussed on the current hot topics of clinical vulnerability and vaccination in MS and was chaired by Professor Mar Tintore, CEMCAT, University Hospital Vall d'Hebron, Barcelona, Spain.
Multiple sclerosis in the ageing population
Over half of the patients with MS in western countries are now 45 years of age or older; a general trend towards increased longevity in patients with MS is noticed [1-4]. Beyond the visible signs of ageing, becoming older also means a higher likelihood of immunosenescence, inflamm-ageing, co-morbidities, and less biological reserve. Not everyone ages equally quickly and chronological and biological age may differ. Patients with MS seem to be susceptible to accelerated biological ageing and may therefore be ‘older’ than their years [5]. At the same time age affects MS [1]. These issues as well as the interplay with co-morbidities have so far received relatively little attention. The objective of this webinar is to shed light on those topics and to discuss how to better consider the special needs of older patients with MS or of those with co-morbidities, in order to ultimately improve the management of the ageing population with MS.
Speaker’s bureau
Mar Tintore, CEMCAT, University Hospital Vall d'Hebron, Barcelona, Spain, Chairperson
Jennifer Graves, University of California San Diego Health, San Diego, CA, USA
Sven Meuth, University Hospital Düsseldorf, Düsseldorf, Germany
MS in the ageing population
References
- Vaughn CB et al. Nat Rev Neurol 2019; 15(6): 329-42 Return to content
- Rotstein DL et al. Neurology 2018; 90(16): e1435-41. Return to content
- Daltrozzo T et al. Front Neurol 2018; 9: 871. Return to content
- UK Government. MS data briefing, February 2020. Available at: https://www.gov.uk/government/publications/multiple-sclerosis-prevalenceincidence-and-smoking-status Return to content
- Wallin MT et al. Neurology 2019; 92(10): e1029-40. Return to content
